Document 0223
 DOCN  M9460223
 TI    Immunopurified clotting factor concentrates.
 DT    9408
 AU    Mariani G; Di Nucci GD; Arcieri P; Department of Human Biopathology,
       University of Rome La Sapienza,; Italy.
 SO    Nouv Rev Fr Hematol. 1994;36 Suppl 1:S61-5. Unique Identifier : AIDSLINE
       MED/94232796
 AB    Monoclonally purified factor concentrates have been available for
       hemophilia treatment since the late 1980's. They are biochemically
       characterized by a high-degree of clotting factor (FVIII or FIX)
       purification and by the virtual lack of contaminants (immunoglobulins,
       fibrinogen and fibronectin). The purification procedure sharply reduces
       the viral load and increases the safety of the concentrate because of
       the viral inactivation procedures. Viral safety is demonstrated by
       prospective studies in previously untreated patients as well as by the
       huge amount of concentrates produced and used so far without reports of
       untoward side effects. Monoclonal concentrates are also safe in terms of
       inhibitor production: they do not elicit the appearance of inhibitors to
       either FVIII or FIX with increased frequency, as shown by data in
       published prospective studies. Prospective studies have recently
       demonstrated that the long-term administration of these high purity
       concentrates does not exert any side effects on the immune system in
       HIV-positive hemophiliacs. The FIX concentrate is also extremely safe in
       terms of thrombotic complications: the highly pure FIX does not activate
       blood coagulation. It has been shown that the monoclonally purified FIX
       concentrate caused no thrombotic events in high-risk surgical patients
       who had previously experienced such complications while on Prothrombin
       Complex Concentrates.
 DE    Antibodies, Monoclonal  Blood Coagulation Factors/ADVERSE
       EFFECTS/*ISOLATION & PURIF/  THERAPEUTIC USE  Hemophilia/THERAPY  Human
       JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).